In the developed xenograft model of HER2-overexpressing tumor, administration of immunonanoparticles showed a much better therapeutic efficacy in inhibiting tumor growth and reducing systemic toxicity of PLGA NPs as compared with free immunotoxin. This evidence concerns the gene ERBB2 and neoplasm.